SAN DIEGO--Trius Therapeutics has brought in MSLGroup to raise awareness of a potential blockbuster drug that treats MRSA infections.
The pharma company is set to launch tedizolid, an antibiotic which is considered particularly promosing in combating rising levels of MRSA infections in hospital and community settings.
Tedizolid is expected to reach the market in 2014, and is projected to earn as much as $1bn in worldwide sales by 2020.
MSLGroup is charged with building awareness of tedizolid, and of Trius’ science, among key hospital audiences. Trius is on track to report topline data in early 2013 and plans to initiate a phase three program for the treatment of pneumonia in the first half of 2013.
Schwartz MSL Boston's Laura Kempke will lead the account, as part of a multi-office, interdisciplinary team that includes Jim Weinrebe, Andrew Law and Ben Navon in Boston, Mike Huckman and Mary Cunney at MSL New York, and Brianne Donahue of Schwartz MSL San Francisco.